key: cord-0719226-pg9x4yea authors: Augustin, Yolanda; Staines, Henry; Krishna, Sanjeev title: Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing date: 2020-10-16 journal: Pharmacol Ther DOI: 10.1016/j.pharmthera.2020.107706 sha: 6f9c698da0b78c19f219389ed14e6bb3ad4c0c8a doc_id: 719226 cord_uid: pg9x4yea Artemisinins are a unique class of antimalarial drugs with significant potential for drug repurposing for a wide range of diseases including cancer. Cancer is a leading cause of death globally and the majority of cancer related deaths occur in Low and Middle Income Countries (LMICs) where conventional treatment options are often limited by financial cost. Drug repurposing can significantly shorten new therapeutic discovery pathways, ensuring greater accessibility and affordability globally. Artemisinins have an excellent safety and tolerability profile as well as being affordable for deployment in Low and Middle Class Income Countries at around USD1 per daily dose. Robust, well designed clinical trials of artemisinin drug repurposing are indicated for a variety of different cancers and treatment settings. Four decades since the discovery of artemisinins for the treatment of malaria by a collaborative research group led by Nobel Prize winner and eminent Chinese scientist Professor Youyou Tu, this class of drugs continue to fascinate and attract significant scientific interest as novel therapeutic agents that could be repurposed to treat a plethora of medical conditions. Artemisinins are a remarkable class of compounds that have shown promising cytotoxic effects against viruses, fungi and a variety of cancers as well as powerful anti-inflammatory effects in animal models of asthma, sepsis, arthritis, pancreatitis, systemic lupus erythematosus and haemorrhagic shock [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . This diverse therapeutic potential has led to artemisinins affordable novel diagnostics and effective therapeutics available in more affluent countries. Drug discovery and novel drug development takes on average [13] [14] [15] years to go from bench to bedside at an average cost of USD1-2 billion 16 . Repurposing of 'old' drugs for new indications can shorten this pathway substantially with significant cost savings. Interestingly, drug repurposing/repositioning is not a new concept. The antimalarial quinine was used in the early 20 th century as an antiarrythmic agent to treat atrial fibrillation. Difluoromethylornithine (DFMO) which was originally developed as an anti-cancer therapy has been repurposed as a treatment for sleeping sickness. To date there are over 100 candidate drugs undergoing drug repurposing clinical trials for cancer. The cancer burden crisis in LMICs is a humanitarian crisis that requires an urgent paradigm shift for which we (as a global community) need to utilise similar principles Studies of artemisinins in in vitro experiments and animal models have demonstrated broad anti-cancer activity including pro-apoptotic, anti-proliferative, anti-angiogenesis and anti-metastatic effects 1, 9, 10 . Artesunate displays cytotoxic effects against numerous cancer cell lines including colon, breast, leukaemia, melanoma, central nervous system, ovarian, renal and prostate cancers 18, 19, 20, 21, 22 . The active from G0/G1 into S phase in pancreatic cell lines via reduction of CDK2, CDK4 and CDK6, cyclin E and NF-κB. Levels of the p27 inhibitory protein were amplified 39 . Artesunate induced radiosensitivity in cervical cancer cell lines by inducing apoptosis and G2/M cell cycle arrest 40 . Endoperoxide bridge cleavage and the formation of alkylating radicals are thought to be key mechanisms underlying the anti-cancer effects of artesunate 19, 20, 33 . Cancer cells are highly proliferative, requiring a heavy iron load which acts as a cofactor in the synthesis of deoxyriboses prior to cell division 41 Artesunate has also been shown to induce oncosis in renal cancer cell lines 39 . Artemisinins have also been shown to regulate the process of autophagy 52 A key hallmark of cancer cells is their ability to detach from the primary tumour, degrade the extracellular matrix and metastasise through the bloodstream 17 . Metalloproteinases (MMPs) play a critical role in tumour migration, invasion and metastases via degradation of the extracellular matrix. E-cadherin is an important cell adhesion molecule. One study in human melanoma cells, showed that artemisinin was able to reduce MMP2 levels thereby blocking cell migration 65 Around a quarter of cancers are attributed to infectious agents that cause chronic inflammation including hepatocellular, bladder, gastric and cervical cancer 55 . Tumour-promoting inflammation is also induced by chemical and environmental human carcinogens, such as tobacco, alcohol, asbestos, aflatoxins and nitrosamines. It is increasingly recognized that these carcinogens can also block the resolution of inflammation resulting in cancer development and progression 75, 79, 80 . Inflammation-induced cell proliferation has been linked to stimulation of carcinogen- Target versatility combined with a high specificity for cancer cells, a low toxicity profile and the absence of cross-resistance to conventional chemotherapeutic agents suggests artesunate as a potent chemotherapeutic agent. One artemisinin in particular, artesunate, has been deployed in a number of clinical translational studies. Artesunate has a hemisuccinate group which confers substantial water-solubility and high oral bioavailability and therefore a convenient Artemisinins: their growing importance in medicine A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer Artemisinins: pharmacological actions beyond anti-malarial The wisdom of crowds and the repurposing of artesunate as an anticancer drug Inhibition of IκB Kinase Attenuates the Organ Injury and Dysfunction Associated with Hemorrhagic Shock Anti-inflammatory and immunoregulatory functions of artemisinin and its derivatives Artesunate relieves lupus nephritis by inhibiting the expression of ICAM-1 Beyond malaria: The inhibition of viruses by artemisinin-type compounds From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy Artesunate Protects Against the Organ Injury and Dysfunction Induced by Severe Hemorrhage and Resuscitation Zhou hou bei ji fang [Emergency Prescriptions kept up one's On Airs, Waters, and Places. 400 B.C. London: Sydenham Society Artemisinin -A Gift from Traditional Chinese Medicine to the World Institute of Chinese Materia Medica Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Can you teach old drugs new tricks? Nature Hallmarks of cancer: the next generation The anti-malarial artesunate is also active against cancer Molecular modes of action of artesunate in tumor cell lines Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells Connexin-43 enhances tumor suppressing activity of artesunate via gap junction-dependent as well as independent pathways in human breast cancer cells. Sci Rep Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy Calcium and survivin are involved in the induction of apoptosis by dihydroartemisinin in human lung cancer SPC-A-1 cells Artesunate Activates the Intrinsic Apoptosis of HCT116 Cells through the Suppression of Fatty Acid Synthesis and the NF-κB Pathway Anticancer Properties of Distinct Antimalarial Drug Classes RIP1-dependent reactive oxygen species Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiog enesis Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51 First study of oral artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor marke rs A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2) Carcinogenesis: Failure of resolution of inflammation? Pharmacol Ther Concordance between sites of tumor development in humans and in experimental animals for 111 agents that are carcinogenic to humans Inflammation-induced DNA damage, mutations and cancer Inflammationinduced cell proliferation potentiates DNA damage-induced mutations in vivo Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases Inflammationinduced cell proliferation potentiates DNA damage-induced mutations in vivo The interplay between inflammation and oxidative stress in carcinogenesis NF-kappaB: linking inflammation and immunity to cancer development and progression Suppression of Oxidative Stress and NFκB/MAPK Signaling by Lyophilized Black Raspberries for Esophageal Cancer Prevention in Rats Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets The Antimalarial Drug Artesunate Attenuates Cardiac Injury in A Rodent Model of Myocardial Infarction Artesunate Protects LPS Induced Acute Lung Injury by Inhibiting TLR4 Expression and Inducing Nrf2 Activation Effects of Artesunate prevent nephritis via the Toll-like receptor /nuclear factor-κB signaling pathway in rats Artesunate Inhibits Renal Ischemia Reperfusion-Stimulated Lung Inflammation in Rats by Activating HO-1 Pathway Artesunate and sorafenib: Combinatorial inhibition of liver cancer cell growth Cancer combination therapy of the sesquiterpenoid artesunate and the selective EGFR-tyrosine kinase inhibitor erlotinib Developing combination of artesunate with paclitaxel loaded into poly-d,l-lactic-co-glycolic acid nanoparticle for systemic delivery to exhibit synergic chemotherapeutic response. Drug Dev Ind Pharm Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens Synthesis of Tamoxifen-Artemisinin and Estrogen-Artemisinin Hybrids Highly Potent Against Breast and Prostate Cancer Artesunate combined with vinorelbine plus cisplatin in treatment of advanced nonsmall cell lung cancer: a randomized controlled trial Anticancer effect of antimalarial artemisinin compounds Molecular modes of action of artesunate in tumor cell lines Dihydroartemisinin induces autophagy by suppressing NF-kappaB activation Dihydroartemisinin potentiates the anticancer effect of cisplatin via mTOR inhibition in cisplatin-resistant ovarian cancer cells: involvement of apoptosis and autophagy Targeting autophagy enhances the anticancer effect of artemisinin and its J o u r n a l P r e -p r o o f derivatives Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis Artesunate Activates the Intrinsic Apoptosis of HCT116 Cells through the Suppression of Fatty Acid Synthesis and the NF-κB Pathway DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis Artesunate activates mitochondrial apoptosis in breast cancer cells via ironcatalyzed lysosomal reactive oxygen species production Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells Artesunate Protects LPS Induced Acute Lung Injury by Inhibiting TLR4 Expression and Inducing Nrf2 Activation Effects of Artesunate prevent nephritis via the Toll-like receptor /nuclear factor-κB signaling pathway in rats Artesunate Inhibits Renal Ischemia Reperfusion-Stimulated Lung Inflammation in Rats by Activating HO-1 Pathway Artesunate and sorafenib: Combinatorial inhibition of liver cancer cell growth Cancer combination therapy of the sesquiterpenoid artesunate and the selective EGFR-tyrosine kinase inhibitor erlotinib Developing combination of artesunate with paclitaxel loaded into poly-d,l-lactic-co-glycolic acid nanoparticle for J o u r n a l P r e -p r o o f Journal Pre-proof systemic delivery to exhibit synergic chemotherapeutic response. Drug Dev Ind Pharm Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens Synthesis of Tamoxifen-Artemisinin and Estrogen-Artemisinin Hybrids Highly Potent Against Breast and Prostate Cancer Anticancer effect of antimalarial artemisinin compounds Molecular modes of action of artesunate in tumor cell lines Dihydroartemisinin potentiates the anticancer effect of cisplatin via mTOR inhibition in cisplatin-resistant ovarian J o u r n a l P r e -p r o o f Journal Pre-proof cancer cells: involvement of apoptosis and autophagy World Health Organisation Public Assessment Reports: Summary of Product Characteristics for Artesunate Artesunate combined with vinorelbine plus cisplatin in treatment of advanced nonsmall cell lung cancer: a randomized controlled trial First study of oral artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor marke rs A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2) Double Blind, Placebo-Controlled Pilot Study ofOral Artesunate Therapy for Colorectal Cancer. EBioMedicine